G
Guest 26753
Oral intake of a cannabinoid together with a meal improved bioavailability by avoiding first-pass metabolism
Researchers of Monash University in Victoria, Australia, investigated the reason why the oral bioavailability of a synthetic cannabinoid receptor agonist (CRA13) was significantly improved if taken together with a meal rich in fat. Oral bioavailability was assessed in human volunteers and in dogs with and without a meal. Food had a substantial positive effect on the oral
bioavailability of CRA13 in human volunteers and in dogs. This cannabinoid is highly lipophilic (soluble in fat) as other cannabinoids including THC.
The absolute bioavailability of the cannabinoid was low in fasted dogs (8-20 per cent), in spite of good absorption (72-75 per cent of radio-labelled CRA13 recovered in the systemic circulation). In fed dogs, bioavailability increased to 47.5 per cent and the majority (43.7 per cent) of the dose was absorbed via the lymphatic system of the intestine. Researchers concluded that the positive food effect for CRA13 does not appear to result from
increased absorption. Rather the increase in bioavailability was stimulated via almost complete transport into the lymph, in turn resulting in a reduction in first-pass metabolism. In fasted dogs most of the cannabinoid was metabolised, i.e. changed to inactive compounds, at once in the liver before reaching the whole body, while the liver was bypassed in fed animals.
(Source: Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, Kretz O, Galli B, Porter CJ.
Intestinal Lymphatic Transport Enhances the Post-Prandial Oral
Bioavailability of a Novel Cannabinoid Receptor Agonist Via
Avoidance of First-Pass Metabolism. Pharm Res. 2009 Mar 12.
Full report is attached below.
Researchers of Monash University in Victoria, Australia, investigated the reason why the oral bioavailability of a synthetic cannabinoid receptor agonist (CRA13) was significantly improved if taken together with a meal rich in fat. Oral bioavailability was assessed in human volunteers and in dogs with and without a meal. Food had a substantial positive effect on the oral
bioavailability of CRA13 in human volunteers and in dogs. This cannabinoid is highly lipophilic (soluble in fat) as other cannabinoids including THC.
The absolute bioavailability of the cannabinoid was low in fasted dogs (8-20 per cent), in spite of good absorption (72-75 per cent of radio-labelled CRA13 recovered in the systemic circulation). In fed dogs, bioavailability increased to 47.5 per cent and the majority (43.7 per cent) of the dose was absorbed via the lymphatic system of the intestine. Researchers concluded that the positive food effect for CRA13 does not appear to result from
increased absorption. Rather the increase in bioavailability was stimulated via almost complete transport into the lymph, in turn resulting in a reduction in first-pass metabolism. In fasted dogs most of the cannabinoid was metabolised, i.e. changed to inactive compounds, at once in the liver before reaching the whole body, while the liver was bypassed in fed animals.
(Source: Trevaskis NL, Shackleford DM, Charman WN, Edwards GA, Gardin A, Appel-Dingemanse S, Kretz O, Galli B, Porter CJ.
Intestinal Lymphatic Transport Enhances the Post-Prandial Oral
Bioavailability of a Novel Cannabinoid Receptor Agonist Via
Avoidance of First-Pass Metabolism. Pharm Res. 2009 Mar 12.
Full report is attached below.